(Q37280804)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18821084%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

review article

1 reference

title

Levodopa-induced dyskinesias and their management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18821084%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18821084%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

author name string

Francesca Del Sorbo

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18821084%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

1 August 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18821084%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18821084%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

volume

255 Suppl 4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18821084%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

issue

S4

1 reference

29 June 2019

page(s)

32-41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18821084%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00415-008-4006-5

14 January 2020

exact match

0 references

cites work

FluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

Neostriatal mechanisms in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

What features improve the accuracy of clinical diagnosis in Parkinson's disease: A clinicopathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

Continuous levodopa infusions to treat complex dystonia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-008-4006-5

Parkinsonism: onset, progression, and mortality

21 January 2018

1 reference

12 December 2020

Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease

1 reference

12 December 2020

Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.

1 reference

12 December 2020

Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease

1 reference

12 December 2020

Pathophysiology of motor complications in Parkinson disease: postsynaptic mechanisms are crucial

1 reference

12 December 2020

Duodenal levodopa infusion in Parkinson's disease--long-term experience

1 reference

12 December 2020

Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.

1 reference

12 December 2020

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

1 reference

12 December 2020

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

1 reference

12 December 2020

STN DBS in PD: selection criteria for surgery should include cognitive and psychiatric factors.

1 reference

12 December 2020

Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations

1 reference

12 December 2020

Preventing levodopa-induced dyskinesias

1 reference

12 December 2020

Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease

1 reference

12 December 2020

Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage

1 reference

12 December 2020

Levodopa-induced dyskinesias

1 reference

12 December 2020

Apomorphine and diphasic dyskinesia

1 reference

12 December 2020

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

1 reference

12 December 2020

Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms

1 reference

12 December 2020

Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias

1 reference

12 December 2020

Control of on/off phenomenon by continuous intravenous infusion of levodopa

1 reference

12 December 2020

D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase.

1 reference

12 December 2020

Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys

1 reference

12 December 2020

Long-term side-effects of levodopa.

1 reference

12 December 2020

Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study

1 reference

12 December 2020

From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity

1 reference

12 December 2020

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group

1 reference

12 December 2020

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology

1 reference

12 December 2020

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

1 reference

12 December 2020

Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations

1 reference

12 December 2020

Development of dyskinesias in a 5-year trial of ropinirole andL-dopa

1 reference

12 December 2020

Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease

1 reference

12 December 2020

"Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease

1 reference

12 December 2020

Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum

1 reference

12 December 2020

A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease

1 reference

12 December 2020

Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study

1 reference

12 December 2020

Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease

1 reference

12 December 2020

Apomorphine-induced dyskinesias after excitotoxic caudate-putamen lesions and the effects of neural transplantation in non-human primates

1 reference

12 December 2020

Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

1 reference

12 December 2020

Gender differences in Parkinson's disease

1 reference

12 December 2020

Letter: Diphasic dyskinesia during levodopa therapy

1 reference

12 December 2020

Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets

1 reference

12 December 2020

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial

1 reference

12 December 2020

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

1 reference

12 December 2020

Levodopa-dyskinesia incidence by age of Parkinson's disease onset

1 reference

12 December 2020

Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.

1 reference

12 December 2020

Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

1 reference

12 December 2020

Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure

1 reference

12 December 2020

Continuous dopaminergic stimulation in Parkinson's disease

1 reference

12 December 2020

L-dopa therapy in Parkinson's disease: a critical review of nine years' experience

1 reference

12 December 2020

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

12 December 2020

[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease

1 reference

12 December 2020

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies

1 reference

12 December 2020

PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum

1 reference

12 December 2020

Impact of the motor complications of Parkinson's disease on the quality of life

1 reference

12 December 2020

Core assessment program for intracerebral transplantations (CAPIT)

1 reference

12 December 2020

Parkin disease: a phenotypic study of a large case series

1 reference

12 December 2020

Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life

1 reference

12 December 2020

Young- versus older-onset Parkinson's disease: impact of disease and psychosocial consequences.

1 reference

12 December 2020

Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

1 reference

12 December 2020

Parkinson's disease: levodopa-induced dyskinesia and signal transduction.

1 reference

12 December 2020

The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport

1 reference

12 December 2020

The PINK1 phenotype can be indistinguishable from idiopathic Parkinson disease

1 reference

12 December 2020

"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy

1 reference

12 December 2020

D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons

1 reference

12 December 2020

Nondopaminergic mechanisms in levodopa-induced dyskinesia

1 reference

12 December 2020

Unified Huntington's disease rating scale: Reliability and consistency

1 reference

12 December 2020

Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism

1 reference

12 December 2020

1 reference

12 December 2020

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

1 reference

12 December 2020